Icon

JAKAFI XR (NDA217180)- (EQ 11MG BASE)

RUXOLITINIB PHOSPHATE INCYTE CORP
EQ 11MG BASE
No No
Expired Expired
None None
None No
JAKAFI/JAKAFI XR is a kinase inhibitor indicated for treatment of:  intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults.  polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea.  steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.  chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 11MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.